A
ATARA BIOTHERAPEUTICS INC
NASDAQ: ATRA (Atara Biotherapeutics, Inc.)
Last update: 1 hour ago9.38
-0.51 (-5.16%)
| Previous Close | 9.89 |
| Volume | 16,034 |
| Price / Earnings (Forward) | 17.70 |
| Price / Sales | 21.52 |
| 52 Weeks Range |
| Profit Margin | -7.83% |
| Operating Margin (TTM) | 49.53% |
| Diluted EPS (TTM) | -2.26 |
| Quarterly Revenue Growth (YOY) | 258.80% |
| Current Ratio (MRQ) | 0.570 |
| Operating Cash Flow (TTM) | -67.24 M |
| Levered Free Cash Flow (TTM) | -62.49 M |
| Return on Assets (TTM) | -1.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Atara Biotherapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
1.6
| Analyst Consensus | NA |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 4.0 |
| Average | 1.61 |
|
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 22.44% |
| % Held by Institutions | 51.06% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ecor1 Capital, Llc | 30 Jun 2026 | 1,552,000 |
| Redmile Group, Llc | 30 Jun 2026 | 441,701 |
| Mackenzie Financial Corp | 30 Jun 2026 | 233,249 |
| Staley Capital Advisers Inc | 30 Jun 2026 | 50,000 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CHERRY BRIAN N | 9.76 | - | 104,166 | 1,016,660 |
| Aggregate Net Quantity | 104,166 | |||
| Aggregate Net Value ($) | 1,016,660 | |||
| Aggregate Avg. Buy ($) | 9.76 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CHERRY BRIAN N | Director | 04 Sep 2026 | Buy (+) | 104,166 | 9.76 | 1,016,660 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |